A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer
Purpose. To evaluate the efficacy and safety of nanosomal docetaxel lipid suspension (NDLS, DoceAqualip) in patients with metastatic castration-resistant prostate cancer (mCRPC). Materials and Methods. In this multicenter, retrospective study, we analyzed the medical charts of mCRPC patients, who we...
Saved in:
Main Authors: | Aseem Samar, Srikant Tiwari, Sundaram Subramanian, Nisarg Joshi, Jaykumar Sejpal, Mujtaba A. Khan, Imran Ahmad |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Prostate Cancer |
Online Access: | http://dx.doi.org/10.1155/2020/4242989 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
by: Filippo Francini, et al.
Published: (2011-01-01) -
Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Seiichi Kato, et al.
Published: (2021-01-01) -
Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
by: Keith L. Davis, et al.
Published: (2015-01-01) -
Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma
by: Osama Diab, et al.
Published: (2019-01-01) -
New Horizons In The Treatment Of Metastatic Castrate Resistant Prostate Cancer
by: Zein El Amir
Published: (2023-06-01)